EASi-KIDNEY™ Phase III trial for people with CKD EASi-KIDNEY™ Phase III trial for people with CKD Boehringer Ingelheim's Sandy Sommer on how treatment innovations in CKD can also improve care for connected conditions, including heart failure.
Survodutide US FDA Breakthrough Therapy phase 3 trials MASH Survodutide US FDA Breakthrough Therapy phase 3 trials MASH Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide
Building Successful Partnerships in Animal Health Building Successful Partnerships in Animal Health Christoph Vetten, Head of Transactions Animal Health, shares his perspectives on how building successful collaborations can drive innovation.
Reimagining digital healthcare worldwide Reimagining digital healthcare worldwide How does our digital lab BI X innovate in Ingelheim and Shanghai? Read about success stories based on different ideation processes
Two new claims for Nexgard range in EU and Australia Two new claims for Nexgard range in EU and Australia Boehringer Ingelheim expands the label claims of its NexGard® brands for the treatment of two severe skin diseases in dogs in the EU and in Australia.
Joint venture to fight Antimicrobial Resistance Joint venture to fight Antimicrobial Resistance Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
S&P Animal Health Partnering Oct 2023 S&P Animal Health Partnering Oct 2023 Interview by S&P Global with Megan Grether, discussing Boehringer Ingelheim Animal Health Partnering’s ambition and approach
Partnership for first-in-class cancer and CRM treatments Partnership for first-in-class cancer and CRM treatments Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments